

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (MN-114)	VAMIKIBART
PRONUNCIATION	va mi' ki bart
THERAPEUTIC CLAIM	Treatment of ocular posterior inflammatory diseases

CHEMICAL NAMES

Immunoglobulin G2 [311-alanine], anti-(human interleukin 6) (human monoclonal RG6179 γ 2-chain), disulfide with human monoclonal RG6179 κ -chain, dimer (ACI)

immunoglobulin G2-kappa, anti-[*Homo sapiens* IL6 (interleukin 6)], humanized and chimeric monoclonal antibody; gamma2 heavy chain humanized (1-448) [VH (*Homo sapiens* IGHV1-69*11 (86.7%) -(IGHD) -IGHJ5*02 (90.9%) L123>T (117), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) - *Homo sapiens* IGHG2*01, G2m.. CH2 V45.1, G2v8 CH2 A93 (CH1 (123-220), hinge 1-12 (221-232), CH2 V45.1 (283), H93>A (311) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-218')-disulfide with kappa light chain chimeric (1'-218') [V-KAPPA *Mus mus*/Homsap (*Mus musculus* IGKV3- 2*01 (79.8%) -IGKJ2*03 (90.9%) S120>Q (104)/*Homo sapiens* IGKV4-1*01 (79.2%) -IGKJ2*01 (100%), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1M, glycoform alfa

STRUCTURAL FORMULA

Heavy Chains: γ 2-chain (H, H')

QVQLVQSGAE	VKKPGSSVKV	SCKASGYVLP	NYLIEWVRQA	PGQGLEWMGV	50
TTPGGGTIN	AQKFQGRVTI	TADESTSTAY	MELSSLRSED	TAVYYCARSR	100
WDPLYYYALE	YWGQGTFTV	SSASTKGPSV	FPLAPCSRST	SESTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSV	VTVPSSNFGT	200
QTYT CNVDHK	PSNTKVDKTV	ERKCCVECPP	CPAPPVAGPS	VFLFPPKPKD	250
TLMISRTPEV	TCVVVDVSHE	DPEVQFNWYV	DGVEVHNAKT	KPREEQFNST	300
FRVSVLTVV	AQDWLNGKEY	KCKVSNKGLP	APIEKTISK	KGQPREPQVY	350
TLPPSREEMT	KNQVSLTCLV	KGFYPSDIAV	EWESNGQPEN	NYKTTTPMLD	400
SDGSFFLYSK	LTVDKSRWQQ	GNVFSCSVMH	EALHNHYTQK	SLSLSPGK	448

Light chains: κ -chain (L, L')

DIVMTQSPDS	LAVSLGERAT	INCRASEVD	NYGIPFMNWY	QQKPGQPPKL	50'
LIYAASNRGS	GVPDRFSGSG	SGTDFTLTIS	SLQAEDVAVY	YCQQSEEVPL	100'
TFGQGTKLEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150'
QWKVDNALQS	GNSQESVTEQ	DSKDSTYLSL	STLTLSKADY	EKHKVYACEV	200'
THQGLSSPVT	KSFNRGEC				218'

Disulfide bridges: in red, bold text, shaded text indicates interchain (total 18 bridges)

Intra-H(C23-C104)	22-96	149-205	262-322	368-426
	22''-96''	149''-205''	262''-322''	368''-426''
Intra-L(C23-C104)	23'-92'	138'-198'		
	23'''-92'''	138'''-198'''		
Inter-H-L(CH1 10-CL 126)	136-218'	136''-218''		
Inter-H-H(h 4, h 5, h 8, h 11)	224-224''	225-225''	228-228''	231-231''

N-terminal glutaminyl cyclization sites: in purple bold text

1 **1''** (H VH Q1) Q> pyroglutamyl (pE, 5-oxoprolyl)

N-Glycosylation sites: in green bold text

298 **298''** (H CH2 N84.4). Fucosylated complex bi-antennary CHO-type glycans

C-terminal lysine clipping: in underlined text

448 448'' (H CHS K2)

CDR-IMGT Regions: in bold light blue (protein sequence numbering from above sequence, not IMGT respective sequence numbering)

Heavy Chain CDR1-3 (H, H'')	26-33 (8)	51-58 (8)	97-111 (15)
	26''-33'' (8)	51''-58'' (8)	97''-111'' (15)
Light Chain CDR1-3 (L', L''')	27'-36' (10)	54'-56' (3)	93'-101' (9)
	27'''-36''' (10)	54'''-56''' (3)	93'''-101''' (9)

MOLECULAR FORMULA C₆₄₆₄H₉₉₈₈N₁₇₁₂O₂₀₃₈S₅₂ (unglycosylated)

MOLECULAR WEIGHT 145.96 kDa (unglycosylated)

TRADEMARK None as yet

SPONSOR Genentech, Inc./Hoffmann-La Roche Inc.

CODE DESIGNATIONS RG6179, RO7200220, EBI-031

CAS REGISTRY NUMBER 2744320-12-3

UNII KP04MH1JTT

WHO NUMBER 12560

gbk